Do sham-controlled versus usual-care CPAP trials give different estimates of HbA1c improvement in sleep apnea with diabetes?

The two designs answer slightly different questions

A usual-care trial asks whether adding CPAP beats whatever care a patient would otherwise get. That is the comparison in the trial of therapeutic CPAP versus usual care, which followed patients with obstructive sleep apnea and type 2 diabetes and reported a decrease in HbA1c, particularly among those starting at 6.5% or above [1]. Because the control group receives ordinary care rather than a fake device, the result bundles together the effect of breathing better at night with everything else that happens to those patients.

A sham-controlled trial asks a narrower question: does real pressure beat a device that feels like treatment but does not splint the airway? That design strips out the ritual of using a machine, the attention of clinic staff, and the expectation of benefit. The review of an artificial-intelligence support system is not that kind of trial either; it compared an AI-supported approach with usual care and reported significantly lower HbA1c in both intervention arms, with CPAP adherence measured at six months [2]. So the two sources here differ in comparison group and in what was being tested, not just in whether a sham was used.

Why a sham can shrink an apparent benefit

If simply wearing a mask and being monitored improves habits or sleep routines, a usual-care comparison will credit CPAP with gains that a sham comparison would attribute to the placebo-like parts of treatment. That is a plausible reason sham-controlled estimates could come out smaller, but it is a mechanism to test rather than something these papers demonstrate. Neither source reports a sham arm, so neither can show how much of the observed HbA1c change survives when the fake device is the comparator.

The usual-care result also depends on who is counted. The reported decrease was concentrated among patients whose HbA1c was at or above 6.5% [1], which means the average improvement in that trial is partly a story about starting level: people with more room to fall can fall further. A sham-controlled trial enrolling a similar group might show a smaller average change for the same reason, or a similar one, and nothing in the available evidence settles which.

What these results can and cannot tell you

The AI review adds a useful caution about what “improvement” means across studies. It reports lower HbA1c in both intervention arms rather than a clean separation between CPAP and control [2], and it tracks CPAP adherence as an outcome in its own right. That pattern is consistent with benefits that are not specific to airway pressure, but it is also consistent with a study too small or too short to separate the arms. The abstract does not give enough detail to choose between those readings.

For a reader trying to judge the size of a CPAP effect, the practical takeaway is that the comparator defines the estimate. A usual-care comparison answers “is CPAP better than what these patients already get,” while a sham comparison answers “is pressure itself doing the work.” The first is the more relevant question for a clinic deciding whether to offer treatment; the second is the more relevant question for understanding why any benefit appears. The evidence here supports the first comparison directly [1] and speaks to the second only indirectly, through a review that did not use a sham [2].

How to read the next CPAP-and-diabetes study you see

Check the control group before the headline number. If the comparison is usual care, expect the estimate to include everything that comes with being treated, and look for whether the benefit was concentrated in people with higher starting HbA1c, as it was in the trial reporting a decrease among those at 6.5% or above [1]. If the comparison is a sham device, expect a smaller number and ask whether the study was long enough and large enough to detect it.

Also check what the study measured alongside HbA1c. The AI review tracked CPAP adherence at six months [2], which matters because a trial can show lower HbA1c in both arms while saying little about whether the machine was used enough to change breathing. A result that reports adherence and HbA1c together is more informative than one that reports only the average glucose marker, whichever comparator it uses.

Sources used in this answer

Related research questions